Phase 3, Randomized, Comparative, Open-label, Parallel Group Study to Compare the Efficacy and Safety of LY3209590 as Weekly Basal Insulin with That of Insulin Glargine in Adults with Type 2 Diabetes Receiving Multiple Daily Injections
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: ELI LILLY AND COMPANY
- Phase: III
- Execution start: 06/10/2022
- End of execution: 30/11/2023
- IP: MIGUEL QUESADA CHARNECO